The Future of Precision Medicine

Orbit Genomics

Orbit Genomics® is redefining precision medicine with OrbiSeq™, the first AI-powered platform that accurately analyzes short tandem repeats—dynamic, stress-responsive DNA sequences that reveal both inherited disease risk and risk acquired from living. Unlike traditional tests focused on static genetic mutations (SNPs), OrbiSeq delivers a personalized, actionable view of health and disease trajectory.

Built on more than two decades of NIH-funded research, the OrbiSeq technology platform unlocks the genomic signals missed by standard sequencing, with validated applications in early disease diagnosis, companion diagnostics, therapeutic target discovery, and aging-related risk. With products in development across cancer, cardiovascular, neurological, and inflammatory diseases, Orbit Genomics is unlocking the missing piece of the genomics puzzle.

News

  • Orbit Genomics Appoints Strategic Communications and Capital Markets Leader Julie Silber to Board of Directors

    Orbit Genomics Appoints Strategic Communications and Capital Markets Leader Julie Silber to Board of Directors

    Orbit Genomics, a pioneer in redefining precision medicine, today announced the appointment of Julie Silber to its Board of Directors. Silber brings over 25 years of experience in investor relations, capital markets, corporate strategy, and board advisory, with expertise in the diagnostics and life sciences sectors to support Orbit’s next phase of growth in precision…


  • Orbit Genomics At MassChallenege Midpoint Road Show

    Orbit Genomics At MassChallenege Midpoint Road Show

    Orbit Genomics thanks the MassChallenge community for an incredible Midpoint Road Show in Dallas last week! The energy, insight, and support from mentors and partners was invaluable—but what stood out most was the camaraderie among the cohort.We are surrounded by an inspiring group of founders who are each tackling MASSive problems in healthcare—from early cancer…